[A preliminary report on the treatment of pleural carcinomatosis with SMANCS].
To clarify the effect of SMANCS on malignant pleural carcinomatosis, seven patients with malignant pleural effusion were treated with SMANCS administered via an intracavitary route. Five patients showed improvement after one or two injections of SMANCS into the thoracic cavity, although 2 patients needed further therapy with the immunopotentiating agent picibanil (OK-432). No serious adverse effects were observed. This simple therapeutic tactic with SMANCS may be effective in cases of malignant pleural carcinomatosis.
Kimura
M
M
Dept. of Surgery, Health Insurance Hitoyoshi General Hospital.
Kaneda
H
H
Kume
S
S
Matsushita
H
H
Inoue
M
M
Kai
M
M
Takeuchi
H
H
Uemura
K
K
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications; D003110:Colonic Neoplasms / Q000150:complications; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000209:etiology; D011137:Polystyrenes / Q000008:administration & dosage / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000150:complications; D009353:Zinostatin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D009353:Zinostatin